Mylan announced that it has received final FDA approval for its Abbreviated New Drug Application (ANDA) for Meclizine HCl Tablets, the generic version of Pfizer‘s Antivert.

Meclizine HCl is an antihistamine indicated for motion sickness prophylaxis and for vertigo of vestibular origin. Meclizine HCl also exerts anticholinergic effects on vestibular afferent nerve terminals and the brainstem to prevent the symptoms of motion sickness.

Meclizine HCl Tablets is being shipped immediately and will be available in 12.5mg, 25mg, and 50mg dosage strengths.

For more information call (800) RX-MYLAN or visit